A 58-year-old man with diabetes mellitus presents with acute onset ptosis and ophthalmoplegia affecting the oculomotor nerve. The pupil is spared. What is the drug of choice for management of the underlying microvascular ischemic third nerve palsy?

Explanation

## Microvascular Ischemic Cranial Nerve Palsies ### Pathophysiology Microvascular ischemic third nerve palsy (also called medical third nerve palsy) occurs due to infarction of the oculomotor nerve fascicles within the midbrain. The pupil is characteristically **spared** because pupillary fibers run on the periphery of the nerve and receive collateral blood supply. ### Risk Factors - Diabetes mellitus (most common) - Hypertension - Hyperlipidemia - Advanced age - Smoking ### Drug of Choice: Aspirin **Key Point:** Aspirin is the first-line antiplatelet agent for acute microvascular ischemic cranial nerve palsies in the setting of vascular risk factors. The evidence supports antiplatelet therapy to prevent recurrent ischemic events and stroke. ### Rationale for Aspirin 1. **Antiplatelet mechanism** — reduces platelet aggregation and thrombotic events 2. **First-line agent** — standard of care for acute ischemic stroke and TIA prevention 3. **Rapid onset** — immediate effect when given acutely 4. **Safety profile** — well-tolerated in acute settings 5. **Cost-effective** — widely available and inexpensive ### Management Algorithm ```mermaid flowchart TD A[Acute cranial nerve palsy]:::outcome --> B{Pupil involved?}:::decision B -->|Yes: Pupil-involving| C[Consider compressive lesion]:::action B -->|No: Pupil-sparing| D[Microvascular ischemic palsy]:::outcome D --> E{Vascular risk factors present?}:::decision E -->|Yes| F[Aspirin 75-325 mg daily]:::action E -->|No| G[Supportive care, observe]:::action F --> H[MRI brain to exclude structural cause]:::action H --> I[Prognosis: spontaneous recovery in 3-6 months]:::outcome ``` **Clinical Pearl:** Pupil-sparing third nerve palsy in a patient with diabetes or hypertension is considered a medical third nerve palsy until proven otherwise. Imaging (MRI) is still recommended to exclude structural lesions, but antiplatelet therapy should be initiated. **High-Yield:** The **pupil-sparing pattern** is the key diagnostic clue — it indicates the lesion is in the nerve fascicles (where pupillary fibers are peripheral and have collateral blood supply) rather than at the nucleus or in a compressive lesion (which would involve pupillary fibers). ### Comparison of Antiplatelet Agents in Acute Ischemia | Agent | Onset | Mechanism | Use in Acute Ischemia | |-------|-------|-----------|----------------------| | **Aspirin** | Immediate | COX inhibition | First-line, acute stroke | | Clopidogrel | 4–6 hours | P2Y12 inhibitor | Delayed onset, not acute monotherapy | | Warfarin | 24–72 hours | Vitamin K antagonist | Too slow for acute ischemia | | Apixaban | Variable | Factor Xa inhibitor | Not indicated for acute ischemic stroke | [cite:Harrison 21e Ch 437]